Ann: Drug Candidate Demonstrates Significant Cardioprotection, page-27

To clarify, 2QFY2025 = 4Q2024 = Oct ~ Dec 2024 = quarter ending December 2024 . (For the newcomers).

"NYR-BI03 is currently undergoing GLP safety and tolerability studies ahead of a first-in-human Phase I clinical trial expected to commence in the quarter ending December 2024.

Thus far, six out of nine GLP studies have been completed.

Subject to satisfactory completion of this Phase I trial, NYR-BI03 has the potential to progress directly to Phase II trials to assess its efficacy in the following" '3' treatment Markets:

1. Stroke

2. Traumatic brain injury, and now

3. Myocardial ischemia-reperfusion injury.

Regarding 3. above, (todays announcement content), currently, "it is a great challenge in the therapy of cardiovascular disease and a common clinical complication".

Current treatment includes Captopril or Capoten, an FDA-approved ACE inhibitor commonly administered following ischhttps://www.sciencedirect.com/science/article/pii/S001948321630236Xemic events and used in this study as a positive control. Captopril is owned by Global BioPharma co. Bristol-Myers Squibb...

https://fintel.io/so/us/bmy

NYR-BIO3 will benefit many humans across the globe if successful.

This is not advice nor is it an intended bias. Please, DYOR.